Business
SPEC: Net loss widened in H1 2024 as SpectraCure advanced Q-PRO® clinical studies and market plans
SPEC: Net loss widened in H1 2024 as SpectraCure advanced Q-PRO® clinical studies and market plans
About this update from Spectracure Ab
SpectraCure reported a net loss of -12,080 TSEK for H1 2024, with stable EPS and strong equity ratio, while advancing clinical studies for its Q-PRO® prostate cancer treatment system and preparing for broader market entry.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.